FAP and neoplasm: Thus, our two main objectives were (i) to select a FAP-scFv which in our selected CAR domain scaffold (Figure 1A), and as an TALEN-gene edited CAR T-cell is safe and effective against human CAFs in vivo and (ii) leverage the ability of FAP CAR T-cells to turn ‘cold’ tumors ‘hot’ to develop combination immunotherapy strategies with higher anti-tumor activity.